Using specific immune cells to fight tumors that lose their antigens
Tumor-specific CD8+ Tc9 cells activate host CD4+ T cells to control antigen-lost tumors
This study is looking at how special immune cells called CD8+ Tc9 cells can help other immune cells fight tumors that have changed and become harder to recognize, with the goal of making cancer treatments more effective for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Methodist Hospital Research Institute NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-11003288 on NIH RePORTER |
What this research studies
This research investigates how a particular type of immune cell, known as CD8+ Tc9 cells, can activate other immune cells (CD4+ T cells) to effectively target and control tumors that have lost their identifying markers. The approach involves adoptive cell transfer, where these Tc9 cells are introduced into the body to enhance the immune response against cancer. By understanding the mechanisms behind this process, the research aims to improve cancer immunotherapy strategies and potentially provide longer-lasting anti-tumor effects for patients.
Who could benefit from this research
Good fit: Ideal candidates for this research would be patients with tumors that have lost their antigens and are seeking innovative immunotherapy options.
Not a fit: Patients with tumors that do not exhibit antigen loss or those who are not eligible for adoptive cell therapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer treatments that harness the body's immune system to fight tumors more efficiently.
How similar studies have performed: Previous research has shown promise in using adoptive cell therapy for cancer treatment, indicating that this approach could lead to significant advancements in immunotherapy.
Where this research is happening
Houston, United States
- Methodist Hospital Research Institute — Houston, United States (Active)
Researchers
- Principal investigator: Yi, Qing — Methodist Hospital Research Institute
- Study coordinator: Yi, Qing
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.